{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:08:31Z","timestamp":1793214511715,"version":"4.5.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1097\/md.0000000000003863","type":"journal-article","created":{"date-parts":[[2016,6,16]],"date-time":"2016-06-16T05:13:57Z","timestamp":1466054037000},"page":"e3863","source":"Crossref","is-referenced-by-count":91,"title":["Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease"],"prefix":"10.1097","volume":"95","author":[{"given":"Toshifumi","family":"Hibi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsei","family":"Hirohata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotoshi","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ukihide","family":"Tateishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiko","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuoki","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Ishigatsubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-28-20211111","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1750-1172-7-20","article-title":"Beh\u00e7et's disease","volume":"7","author":"Saadoun","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"R2-28-20211111","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s10238-004-0033-4","article-title":"Behcet's disease","volume":"3","author":"Suzuki Kurokawa","year":"2004","journal-title":"Clin Exp Med"},{"key":"R3-28-20211111","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/MD.0b013e318211bf28","article-title":"Beh\u00e7et disease: evolution of clinical manifestations","volume":"90","author":"Ideguchi","year":"2011","journal-title":"Medicine"},{"key":"R4-28-20211111","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s12328-014-0488-0","article-title":"Diagnosis and management of intestinal Beh\u00e7et's disease","volume":"7","author":"Hisamatsu","year":"2014","journal-title":"Clin J Gastroenterol"},{"key":"R5-28-20211111","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.autrev.2011.11.026","article-title":"New insights into the pathogenesis of Beh\u00e7et's disease","volume":"11","author":"Pineton de Chambrun","year":"2012","journal-title":"Autoimmun Rev"},{"key":"R6-28-20211111","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1365-2249.2005.02695.x","article-title":"Involvement of Th1 cells and heat shock protein 60 in the pathogenesis of intestinal Beh\u00e7et's disease","volume":"139","author":"Imamura","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"R7-28-20211111","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/intimm\/dxt046","article-title":"Novel NLRP3\/cryopyrin mutations and pro-inflammatory cytokine profiles in Beh\u00e7et's syndrome patients","volume":"26","author":"Y\u00fcksel","year":"2014","journal-title":"Int Immunol"},{"key":"R8-28-20211111","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.2169\/internalmedicine.51.8583","article-title":"Changes in biomarkers focused on differences in disease course or treatment in patients with neuro-Beh\u00e7et's disease","volume":"51","author":"Hirohata","year":"2012","journal-title":"Intern Med"},{"key":"R9-28-20211111","first-page":"1362","article-title":"Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Beh\u00e7et's disease with refractory uveoretinitis","volume":"31","author":"Ohno","year":"2004","journal-title":"J Rheumatol"},{"key":"R10-28-20211111","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/gut.49.5.725","article-title":"Treatment of intestinal Beh\u00e7et's syndrome with chimeric tumour necrosis factor alpha antibody","volume":"49","author":"Travis","year":"2001","journal-title":"Gut"},{"key":"R11-28-20211111","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/ibd.20457","article-title":"Efficacy of infliximab for induction and maintenance of remission in intestinal Beh\u00e7et's disease","volume":"14","author":"Naganuma","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"R12-28-20211111","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.2169\/internalmedicine.52.0589","article-title":"Efficacy of infliximab in patients with intestinal Beh\u00e7et's disease refractory to conventional medication","volume":"52","author":"Kinoshita","year":"2013","journal-title":"Intern Med"},{"key":"R13-28-20211111","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1136\/jnnp.2004.055434","article-title":"Efficacy of TNF \u03b1 blockade in cyclophosphamide resistant neuro-Beh\u00e7et disease","volume":"76","author":"Ribi","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R14-28-20211111","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/ard.2006.056804","article-title":"Successful treatment of refractory neuro- Beh\u00e7et disease with infliximab: a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile","volume":"66","author":"Fujikawa","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R15-28-20211111","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jns.2008.05.002","article-title":"Effect of infliximab in progressive neuro-Beh\u00e7et's syndrome","volume":"272","author":"Kikuchi","year":"2008","journal-title":"J Neurol Sci"},{"key":"R16-28-20211111","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/acr.21557","article-title":"Beh\u00e7et's disease: successful treatment with infliximab in 7 patients with severe vascular manifestations. A retrospective analysis","volume":"64","author":"Adler","year":"2012","journal-title":"Arthritis Care Res"},{"key":"R17-28-20211111","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","article-title":"Efficacy of anti-TNF alpha in severe and\/or refractory Beh\u00e7et's disease: multicenter study of 124 patients","volume":"62","author":"Vallet","year":"2015","journal-title":"J Autoimmun"},{"key":"R19-28-20211111","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor \u03b1 monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum"},{"key":"R20-28-20211111","doi-asserted-by":"crossref","first-page":"R109","DOI":"10.1186\/ar3043","article-title":"Phenotype and functional changes of V\u03b39\/V\u03b42 T lymphocytes in Beh\u00e7et's disease and the effect of infliximab on Vgamma9\/Vdelta2 T cell expansion, activation and cytotoxicity","volume":"12","author":"Accardo-Palumbo","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"R21-28-20211111","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.cgh.2014.08.042","article-title":"Adalimumab for the treatment of Japanese patients with intestinal Beh\u00e7et's disease","volume":"13","author":"Tanida","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R22-28-20211111","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s12013-014-9860-4","article-title":"Etanercept in the treatment of intestinal Behcet's disease","volume":"69","author":"Ma","year":"2014","journal-title":"Cell Biochem Biophys"},{"key":"R23-28-20211111","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1007\/s10620-014-3198-z","article-title":"Mucosal healing predicts the long-term prognosis of intestinal Beh\u00e7et's disease","volume":"59","author":"Yim","year":"2014","journal-title":"Dig Dis Sci"},{"key":"R24-28-20211111","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3109\/s10165-011-0533-5","article-title":"Clinical characteristics of neuro-Behcet's disease in Japan: a multicenter retrospective analysis","volume":"22","author":"Hirohata","year":"2012","journal-title":"Mod Rheumatol"},{"key":"R25-28-20211111","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s10067-005-0046-8","article-title":"Quality of life and life satisfaction in patients with Beh\u00e7et's disease: relationship with disease activity","volume":"25","author":"Bodur","year":"2006","journal-title":"Clin Rheumatol"},{"key":"R26-28-20211111","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1136\/ard.2006.065995","article-title":"Double-blinded infliximab dose escalation in patients with rheumatoid arthritis","volume":"66","author":"Rahman","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R27-28-20211111","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3109\/s10165-009-0195-8","article-title":"Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study","volume":"19","author":"Takeuchi","year":"2009","journal-title":"Mod Rheumatol"},{"key":"R28-28-20211111","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1097\/MIB.0000000000000475","article-title":"Circulating interleukin 6 and albumin, and infliximab levels are good predictors of recovering efficacy after dose escalation infliximab therapy in patients with loss of response to treatment for Crohn's disease: a prospective clinical trial","volume":"21","author":"Suzuki","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"R29-28-20211111","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/art.10302","article-title":"The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial","volume":"46","author":"St Clair","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R30-28-20211111","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"R31-28-20211111","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/ibd.21886","article-title":"Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn's disease","volume":"18","author":"Hibi","year":"2012","journal-title":"Inflamm Bowel Dis"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201606140-00028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T20:00:50Z","timestamp":1636660850000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201606140-00028"}},"subtitle":["Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study"],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":30,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000003863","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]}}}